Chimeric Therapeutics Limited has released a press release.
CHM announces positive Phase 1/2 data at ASCO
Earlier from Chimeric Therapeutics
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- Consolidation/Split - CHM
- Chimeric receives $1.8 M advance on FY26 R&D tax incentive
- Half Year Report and Appendix 4D 31 December 2025